9-Jun-2026
No headlines found.
Globe Newswire (Thu, 4-Jun 8:00 AM ET)
Celularity Releases CEO Letter to Shareholders
Globe Newswire (Wed, 3-Jun 4:15 PM ET)
Celularity Appoints Rick Gonzalez as Chief Commercial Officer
Globe Newswire (Wed, 3-Jun 8:00 AM ET)
Celularity Receives Nasdaq Notice Regarding Form 10-Q
Globe Newswire (Fri, 29-May 5:15 PM ET)
Globe Newswire (Fri, 1-May 4:30 PM ET)
NEXGEL Appoints Ian Blackman as Chief Financial Officer
Globe Newswire (Mon, 27-Apr 9:00 AM ET)
Globe Newswire (Tue, 21-Apr 9:00 AM ET)
Celularity Announces Closing of Transaction with NexGel
Globe Newswire (Tue, 21-Apr 8:30 AM ET)
Celularity Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing
Globe Newswire (Fri, 17-Apr 4:35 PM ET)
Globe Newswire (Thu, 12-Mar 8:45 AM ET)
Celularity Inc is a regenerative and cellular medicine company focused on developing placental-derived allogeneic cell therapies and biomaterial products for the treatment of degenerative diseases, aging-related conditions, cancer, and immune disorders. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It generates the majority of its revenue from the Degenerative Disease segment.
Celularity - Class A trades on the NASDAQ stock market under the symbol CELU.
As of June 9, 2026, CELU stock price declined to $0.69 with 134,498 million shares trading.
CELU has a beta of 1.08, meaning it tends to be more sensitive to market movements. CELU has a correlation of 0.02 to the broad based SPY ETF.
CELU has a market cap of $19.61 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, CELU traded as high as $8.90 and as low as $.67.
The top ETF exchange traded funds that CELU belongs to (by Net Assets): VTI, VXF, IWC.
CELU has underperformed the market in the last year with a price return of -66.9% while the SPY ETF gained +24.3%. CELU has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -43.1% and -20.9%, respectively, while the SPY returned +9.9% and -1.2%, respectively.
CELU support price is $.76 and resistance is $.87 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CELU shares will trade within this expected range on the day.